Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187559 | 0.87 | CYP2C19 (0.52) | ACHEKMT2AALDH1A1CYP2C19NPSR1 | |
| SCHEMBL803545 | 0.83 | SMN1; SMN2 (0.43) | TAS1R3TAS1R1BCHEACHEMEN1 | |
| SCHEMBL16865531 | 0.82 | MT-CO2 (0.55) | TAS1R3TAS1R1BCHEACHEMEN1 | |
| SCHEMBL19986355 | 0.79 | TAS1R3 (0.45) | TAS1R3TAS1R1GRM4BCHEACHE | |
| SCHEMBL16865514 | 0.79 | TAS1R3 (0.48) | TAS1R3TAS1R1BCHEACHEMEN1 | |
| SCHEMBL5700815 | 0.78 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1CYP2C19LMNA | |
| SCHEMBL5485178 | 0.77 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1CYP2C19TSHR | |
| SCHEMBL4779827 | 0.75 | L3MBTL1 (0.49) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL5487986 | 0.75 | SLC6A3 (0.57) | ALDH1A1TSHRLMNA | |
| SCHEMBL11458699 | 0.74 | CYP1A2 (0.42) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | TAS1R3 3512/4885TAS1R1 3477/4885GRM4 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.